Mosby's 2014 Nursing Drug Reference (290 page)

BOOK: Mosby's 2014 Nursing Drug Reference
3.29Mb size Format: txt, pdf, ePub
ads
NIFEdipine (Rx)

(nye-fed′i-peen)

Adalat CC, Afeditab CR, Apo-Nifed
, Apo-Nifed PA
, Nifediac CC, Nifedical XL, Procardia, Procardia XL

Func. class.:
Calcium channel blocker, antianginal, antihypertensive

Chem. class.:
Dihydropyridine

Do not confuse:
NIFEdipine
/niCARdipine/niMODipine

ACTION:

Inhibits calcium ion influx across cell membrane during cardiac depolarization; relaxes coronary vascular smooth muscle; dilates coronary arteries; increases myocardial oxygen delivery in patients with vasospastic angina; dilates peripheral arteries

USES:

Chronic stable angina pectoris, vasospastic angina, hypertension

Unlabeled uses:
Migraines, preterm labor, chronic/acute hypertension (pediatrics), diabetic nephropathy, proteinuria, hiccups

CONTRAINDICATIONS:

Hypersensitivity to this product or dihydropyridine; cardiogenic shock

Precautions:
Pregnancy (C), breastfeeding, children, CHF, hypotension, sick sinus syndrome, 2nd-/3rd-degree heart block, hypotension <90 mm Hg systolic, hepatic injury, renal disease, acute MI, aortic stenosis, GERD, heart failure

DOSAGE AND ROUTES
Calculator

• Adult:
PO
Immediate release 10 mg tid, increase in 10-mg increments q7-14days, max 180 mg/24 hr or single dose of 30 mg;
SUS REL
30-60 mg/day, may increase q7-14days, max 90 mg/day

Hypertension

• Adult:
PO EXT REL
30-60 mg daily, titrate upward as needed, max 90 mg/day (Adalat CC), 120 mg/day (Procardia XL)

• Child/adolescent (unlabeled):
PO EXT REL
0.25-0.5 mg/kg/day, max 3 mg/kg/day

Acute hypertensive episodes in pediatric patients (unlabeled)

• Adolescent/child/infant:
PO
0.2-0.5 mg/kg/dose up to 10 mg (total dose)

Migraine prophylaxis (unlabeled)

• Adult:
PO
30-180 mg/day

Preterm labor (unlabeled)

• Pregnant female:
PO
Immediate release (Procardia, Adalat) 30-mg loading dose then 10-20 mg q4-6hr; use in monitored settings

Available forms:
Caps 5
, 10, 20 mg; ext rel tabs (CC, XL) 10
, 20
, 30, 60, 90 mg; tabs 10 mg

Administer:

• 
Do not break, crush, or chew ext rel tabs, do not use immediate release caps within 7 days of MI, coronary syndrome

• 
Without regard to meals; avoid grapefruit juice

• 
Protect caps from direct light, keep in dry area, do not freeze

SIDE EFFECTS

CNS:
Headache
, fatigue, drowsiness,
dizziness
, anxiety, depression, weakness, insomnia, light-headedness, paresthesia, tinnitus, blurred vision, nervousness, tremor,
flushing

CV:
Dysrhythmias,
edema, hypotension, palpitations, tachycardia

GI:
Nausea, vomiting, diarrhea, gastric upset, constipation, increased LFTs, dry mouth, flatulence, gingival hyperplasia

GU:
Nocturia, polyuria

HEMA:
Bruising, bleeding, petechiae

INTEG:
Rash, pruritus, flushing, hair loss,
Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis

MISC:
Sexual difficulties, cough, fever, chills

PHARMACOKINETICS

Metabolized by liver; excreted in urine 60%-80% (metabolites), feces 15%; protein binding 90%-98%

PO:
Onset 20 min, peak 0.5-6 hr, duration 6-8 hr, half-life 2-5 hr, well absorbed

PO-ER:
Duration 24 hr

INTERACTIONS

 
Contraindicated with strong CYP3A4 inducers

Increase:
level of digoxin, phenytoin, cycloSPORINE, prazosin, carBAMazepine

 
Increase:
NIFEdipine, toxicity—cimetidine, ranitidine

Increase:
effects of β-blockers, antihypertensives

Decrease:
antihypertensive effect—NSAIDs

Decrease:
effects of quiNIDine

Decrease:
NIFEdipine level—smoking

Drug/Herb

Increase:
effect—ginkgo biloba, ginseng, hawthorn

Decrease:
effect—ephedra, melatonin, St. John’s wort, yohimbe

Drug/Food

Increase:
NIFEdipine level—grapefruit juice

Drug/Lab Test

Increase:
CPK, LDH, AST

Positive:
ANA, direct Coombs’ test

NURSING CONSIDERATIONS
Assess:

• 
Anginal pain:
location, intensity, duration, character, alleviating, aggravating factors

• 
Cardiac status: B/P, pulse, respiration, ECG at baseline and periodically, in those taking antihypertensives, β-blockers, monitor B/P often

• 
Potassium, renal, hepatic studies periodically during treatment

• 
For bruising, petechiae, bleeding

• 
GI obstruction:
Ext rel products have been associated with rare reports of obstruction in those with strictures and no known GI disease

• 
Serious skin disorders:
rash that starts suddenly, fever, cutaneous lesions that may have pustules present; discontinue product

Evaluate:

• 
Therapeutic response: decreased anginal pain, B/P, activity tolerance

Teach patient/family:

• 
To avoid hazardous activities until stabilized on product, dizziness is no longer a problem

• 
To limit caffeine consumption; to avoid alcohol products

• 
To avoid OTC products unless directed by prescriber without regard to meals, Adelat CC should be taken on empty stomach

• 
That empty tab shells may appear in stools and is not significant

• 
Hypertension:
to comply with all areas of medical regimen: diet, exercise, stress reduction, product therapy

• 
To change position slowly because orthostatic hypotension is common

 
To notify prescriber of dyspnea, edema of extremities, nausea, vomiting, severe ataxia, severe rash; changes in pattern, frequency, severity of angina

• 
To increase fluid intake to prevent constipation

• 
To check for gingival hyperplasia and report promptly

• 
Not to discontinue abruptly; to gradually taper

BOOK: Mosby's 2014 Nursing Drug Reference
3.29Mb size Format: txt, pdf, ePub
ads

Other books

Amor, curiosidad, prozac y dudas by Lucía Etxebarría
Savage Betrayal by Scott, Theresa
La tregua by Mario Benedetti
12 Borrowing Trouble by Becky McGraw
The World We Found by Thrity Umrigar
Venus Rising by Speer, Flora